Technology · 06/10/20261 min read
FDA Requests Information on Design and Safety Considerations for Ibogaine Clinical Trials
The US Food and Drug Administration (FDA) is seeking public input on its approach to designing early-phase clinical trials for ibogaine-based medications, as part of its efforts to ensure the safety and efficacy of these treatments.
Original source language: Federal Register — Health and Human ServicesOpen original release →